Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2001, p. 2151-2153, Vol. 45, No. 7
Department of Microbiology, Asesoría
Científica y de Investigación Aplicada, 08037 Barcelona,1 and Unitat de
Microbiologia, Facultat de Medicina, and Institut d'Estudis
Avançats, Universitat Rovira i Virgili, 43201 Reus,2 Spain
Received 30 January 2001/Returned for modification 22 February
2001/Accepted 9 April 2001
In order to develop new approaches to the treatment of the severe
and usually fatal infections caused by Scedosporium
spp., the in vitro antifungal activities of four novel triazoles
(posaconazole, ravuconazole, voriconazole, and UR-9825) and some
current antifungals (amphotericin B, ketoconazole, itraconazole,
and nystatin) were determined. The latter group was clearly
ineffective against the two species tested. The four new antifungals
showed activity against Scedosporium apiospermum, and
UR-9825 and voriconazole were active against S.
prolificans.
The anamorph genus
Scedosporium comprises two important pathogens to humans,
Scedosporium apiospermum, the asexual state of Pseudallescheria boydii, and S. prolificans.
Previously, both species were associated mainly with localized
infections. Generally, S. apiospermum was associated with
white-grain mycetoma and S. prolificans was associated with
subcutaneous infections, with a predilection for cartilage and joint
areas (2, 4, 6, 14). However, in recent years both species
have evolved into important agents causing disseminated infections,
mainly in neutropenic patients. Unfortunately, these infections are
usually unresponsive to antifungals and their management becomes very difficult.
In disseminated-infection cases, S. apiospermum shows a
marked predilection for the central nervous system (9).
The invasive infections caused by S. prolificans usually
involve patients with underlying blood malignancies and are usually
fatal. These patients have generally been treated with amphotericin B
and occasionally with other antifungals, such as itraconazole,
flucytosine, fluconazole, or miconazole, but commonly with unsuccessful
outcomes. The prognosis is worse for S. prolificans
infections because in only a few cases has the infection been overcome
and then only after resolution of the underlying neutropenia. The in
vitro susceptibility of S. prolificans to the traditional
antifungals has been tested in several studies (3, 8, 15;
J. Guarro, J. Cano, J. Gené, M. Solé, and A. J. Carrillo-Muñoz, Abstr. 14th Congr. Int. Soc. Hum. Anim. Mycol.,
p. 84; P. Pacheco, D. Sutton, A. Fothergill, and M. Rinaldi,
Abstr. 14th Congr. Int. Soc. Hum. Anim. Mycol., abstr. 79, p. 234), and
although the methodological conditions differed between the
laboratories, in general, their results correlate with the observed
poor clinical responses. In this study, we evaluated the inhibitory
activities of four novel triazoles (ravuconazole, posaconazole,
voriconazole, and UR-9825) and some current ones, such as amphotericin
B, ketoconazole, itraconazole, and nystatin, against 33 clinical
isolates of S. prolificans and 11 of S. apiospermum. The isolates were tested by a previously described
microdilution method (12), using sterile, 96-well
microplates, mainly according to the guidelines of the National
Committee for Clinical Laboratory Standards for molds
(11).
The isolates, from very diverse clinical sources, were supplied by
different Spanish hospitals. They were identified at the Microbiology
Unit of the Medical School of the Rovira i Virgili University at Reus,
Spain. The isolates, stored in sterile, distilled water until the time
of study, were subcultured onto potato dextrose agar (Difco
Laboratories, Detroit, Mich.) at 30°C for 7 days to ensure the
viability, purity, and sporulation of the inoculum. Amphotericin B,
ravuconazole, nystatin (Bristol-Myers Squibb, Princeton, N.J.),
ketoconazole, itraconazole (Janssen Research Foundation, Beerse,
Belgium), voriconazole (Pfizer Ltd., Sandwich, United Kingdom),
posaconazole (Schering-Plough, Kenilworth, N.J.), and UR 9825 (J. Uriach & Cia, SA, Barcelona, Spain) were tested in RPMI 1640 medium
buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid (MOPS).
Aliquots of 100 µl of the drug dilutions were inoculated into the
wells of microplates, which were stored at All isolates produced detectable growth after 72 h of incubation;
therefore, MICs were determined at this time interval. The MICs of all
eight drugs for all 44 isolates are summarized in Table
1. The four current antifungals
(amphotericin B, nystatin, itraconazole, and ketoconazole) showed very
high MICs against both species. Amphotericin B, the drug commonly used
to treat these infections, presented geometric mean MICs of 6.48 µg/ml against S. prolificans and 4 µg/ml against
S. apiospermum. We observed a strain-dependent in vitro
response to amphotericin B, as pointed out by Walsh et al.
(15); thus, while the MICs for most of the strains were
high, two strains of S. prolificans were susceptible to this
drug (MIC, 0.125 µg/ml). By contrast, for all of the strains of
S. apiospermum, the MICs were
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2151-2153.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
In Vitro Activities of Four Novel Triazoles against
Scedosporium spp.
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
70°C until they were
used. The inoculum was prepared by removing the sporulated fungi from
the agar slant with a loop and suspending them in 10 ml of sterile
water. The suspension was adjusted to 68 to 70% transmittance at 530 nm and diluted 10-fold to yield a working suspension of 0.4 × 104 to 5 × 104
CFU/ml. The concentrations of the test drugs were 0.016 to 16 µg/ml.
The temperature of incubation was 35°C, and MIC readings were made
after 48 and 72 h. The amphotericin B and nystatin MICs were
defined as the lowest drug concentrations at which there was a complete
absence of growth. The MICs of the azoles were defined as the lowest
drug concentrations that led to a 50% inhibition of growth in
comparison to controls. Paecilomyces variotii ATCC 36257 was
used as a quality control strain. The data are presented as MIC ranges,
geometric mean MICs, and the MICs required to inhibit 50 and 90% of
the isolates of each species (MIC50 and
MIC90, respectively).
2 µg/ml. The results
displayed by the four novel triazoles varied according to the species.
Ravuconazole, posaconazole, and voriconazole were very active against
S. apiospermum, their geometric mean MICs being 0.125, 0.08, and 0.06 µg/ml, respectively, and none showed a MIC higher than 0.25 µg/ml against any strain. UR-9825 showed slightly lower activity
against this species, i.e., a mean MIC of 1 µg/ml. In the case of
S. prolificans, the results obtained with the four triazoles
were the reverse of those against the other species; i.e., UR-9825
showed the best activity. The mean MICs of ravuconazole, posaconazole,
and voriconazole were 8.9, 10.5, and 1.83 µg/ml, respectively, and
that of UR-9825 was 0.35 µg/ml. The MICs for the quality control
strain were as follows: amphotericin B, 0.06 µg/ml; nystatin, 0.125 µg/ml; itraconazole and ketoconazole, 0.03 µg/ml; ravuconazole,
posaconazole, voriconazole, and UR-9825, 0.06 µg/ml.
TABLE 1.
Antifungal suceptiblities of Scedosporium
spp.a
The results obtained with amphotericin B, itraconazole, and ketoconazole agree with those of other authors who used the same microdilution method and followed the NCCLS guidelines (11). However, in the case of voriconazole, we observed important discrepancies. Cuenca-Estrella et al. (3) reported a MIC range of 8 to 32 µg/ml and a MIC90 of 16 µg/ml against S. prolificans and a MIC range of 0.5 to 2 µg/ml and a MIC90 of 2 µg/ml against S. apiospermum. In our study, these values were considerably lower, i.e., 0.06 to 4 and 4 µg/ml, respectively, against S. prolificans and 0.01 to 0.25 and 0.25 µg/ml, respectively, against S. apiospermum. These discrepancies can be explained, in part, by some differences in methodological procedure. Those authors used RPMI medium-2% glucose and a final inoculum suspension of 105 CFU/ml, and the MIC was always defined as the lowest concentration that completely inhibited fungal growth. We used the 50% reduction endpoint. If, instead, we had used the criterion of complete inhibition, the MICs would have increased, in general, by more than 2 dilutions. Despite its being generally accepted that the MIC endpoint definition is crucial, there is still no universal consensus on what is appropriate. However, for voriconazole, some clinical results exist on the treatment of S. apiospermum infections that seem to correlate better with lower MICs, i.e., those obtained with the less strict criterion. Treatment with voriconazole has had a good clinical outcome for three patients with S. apiospermum invasive infection (5, 7, 10). Therefore, the MICs obtained in our study are apparently more predictive than those obtained by Cuenca-Estrella et al. (3). With S. apiospermum, we also observed important differences from the results of other authors. Walsh et al. (15) reported mean MICs of amphotericin B and itraconazole of 1.1 and 0.45 µg/ml, respectively, versus the 4 and 4.5 µg/ml obtained in our study. Those authors used the broth macrodilution method, and although we have demonstrated here that the broth macro- and microdilution methods for testing of the antifungal susceptibilities of some filamentous fungi (12) produced similar results, the use of two different techniques could be the cause of such differences.
It is worth mentioning that in our study, UR-9825 was very effective against S. prolificans. This drug is a potent new triazole derivative that showed efficacy in vitro against pathogenic yeasts (13) and in animal models of candidiasis and aspergillosis (1), and our results suggest that UR-9825 should be considered for further study in the treatment of S. prolificans. Another promising approach is the combination of antifungal drugs with different mechanisms of action. Meletiadis et al. (8) have recently reported an in vitro synergistic effect of the terbinafine-itraconazole combination against S. prolificans. Walsh et al. (15) reported a lack of in vitro fungicidal effect of either amphotericin B or azoles against S. apiospermum. By contrast, they noticed augmented antifungal activity with amphotericin B-azole (miconazole, itraconazole, or fluconazole) combinations. Further studies with these approaches in appropriate animal models are required in order to develop therapeutic strategies for the treatment of the severe and nearly always fatal infections caused by these fungi in neutropenic patients.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Unitat de Microbiologia, Facultat de Medicina, Universitat Rovira i Virgili, C/St. Llorenç, 21, 43201 Reus, Spain. Phone: (34) 977-759359. Fax: (34) 977-759322. E-mail: umb{at}fmcs.urv.es.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Bartrolí, J., E. Turmo, M. Algueró, E. Boncompte, M. L. Vericat, L. Conte, J. Ramis, M. Merlos, J. García-Rafanell, and J. Forn. 1998. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted 4(3H)-quinazolinones. J. Med. Chem. 41:1869-1882[CrossRef][Medline]. |
| 2. | Berenguer, J., J. L. Rodriguez-Tudela, C. Richard, M. Alvárez, M. A. Sanz, L. Gaztelurrutia, J. Ayats, and J. V. Martinez-Suárez. 1997. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Medicine (Baltimore) 76:256-265[CrossRef][Medline]. |
| 3. |
Cuenca-Estrella, M.,
B. Ruiz-Diez,
J. V. Martínez-Suárez,
A. Monzon, and J. L. Rodriguez-Tudela.
1999.
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
J. Antimicrob. Chemother.
43:149-151 |
| 4. | de Hoog, G. S., and J. Guarro (ed.). 1995. Atlas of clinical fungi. Centraalbureau voor Schimmelcultures, Baarn, The Netherlands. |
| 5. |
Girmenia, C.,
G. Luzi,
M. Monaco, and M. Pietro.
1998.
Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.
J. Clin. Microbiol.
36:1436-1438 |
| 6. | Gosbell, I. B., M. L. Morris, J. G. Gallo, K. A. Weeks, S. A. Neville, A. H. Rogers, R. H. Andrews, and D. H. Ellis. 1999. Clinical, pathologic and epidemiologic features of infection with Scedosporium prolificans: four cases and review. Clin. Microbiol. Infect. 5:672-686. |
| 7. | Jabado, N., J. L. Casanova, E. Haddad, F. Dulieu, J. C. Fournet, B. Dupont, A. Fischer, C. Hennequin, and S. Blanche. 1998. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis. 27:1437-1441[Medline]. |
| 8. |
Meletiadis, J.,
J. W. Mouton,
J. L. Rodriguez-Tudela,
F. G. M. Meiss, and P. E. Verweij.
2000.
In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.
Antimicrob. Agents Chemother.
44:470-472 |
| 9. | Montero, A., J. E. Cohen, M. A. Fernández, G. Mazzolini, R. Gómez, and J. Perugini. 1998. Cerebral pseudallescheriasis due to Pseudallescheria boydii as the first manifestation of AIDS. Clin. Infect. Dis. 26:1476-1477[Medline]. |
| 10. | Muñoz, P., M. Marín, P. Tornero, P. M. Rabadán, M. Rodriguez-Creixéms, and E. Bouza. 2000. Successful outcome of Scedosporium apiospermum disseminated infections treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis. 31:1499-1501[CrossRef][Medline]. |
| 11. | National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 12. | Pujol, I., J. Guarro, C. Llop, L. Soler, and J. Fernández-Ballart. 1996. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for filamentous fungi. Antimicrob. Agents Chemother. 41:808-811[Abstract]. |
| 13. |
Ramos, G.,
M. Cuenca-Estrella,
A. Monzón, and J. L. Rodríguez-Tudela.
1999.
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
J. Antimicrob. Chemother.
44:283-286 |
| 14. | Tadros, T. S., K. Workowski, R. J. Siegel, S. Hunter, and D. A. Schwartz. 1998. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Human Pathol. 29:1266-1272[CrossRef][Medline]. |
| 15. | Walsh, T. J., J. Peter, D. A. McGough, A. W. Fothergill, M. G. Rinaldi, and P. A. Pizzo. 1995. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob. Agents Chemother. 39:1361-1364[Abstract]. |
Antimicrobial Agents and Chemotherapy, July 2001, p. 2151-2153, Vol. 45, No. 7
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2151-2153.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Karlsson, M. O., Lutsar, I., Milligan, P. A.
(2009). Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies. Antimicrob. Agents Chemother.
53: 935-944
[Abstract] [Full Text] -
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., Rinaldi, M. G., Shea, Y. R., Zaoutis, T., Kottilil, S., Walsh, T. J.
(2008). Infections Caused by Scedosporium spp.. Clin. Microbiol. Rev.
21: 157-197
[Abstract] [Full Text] -
Goodwin, M. L., Drew, R. H.
(2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother
61: 17-25
[Abstract] [Full Text] -
Caira, M., Girmenia, C., Valentini, C. G., Sanguinetti, M., Bonini, A., Rossi, G., Fianchi, L., Leone, G., Pagano, L.
(2008). Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. haematol
93: 104-110
[Abstract] [Full Text] -
Gilgado, F., Serena, C., Cano, J., Gene, J., Guarro, J.
(2006). Antifungal Susceptibilities of the Species of the Pseudallescheria boydii Complex. Antimicrob. Agents Chemother.
50: 4211-4213
[Abstract] [Full Text] -
Enoch, D. A., Ludlam, H. A., Brown, N. M.
(2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol
55: 809-818
[Abstract] [Full Text] -
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M.
(2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother.
50: 2009-2015
[Abstract] [Full Text] -
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Monzon, A., Rodriguez-Tudela, J. L.
(2005). In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi. Antimicrob. Agents Chemother.
49: 5136-5138
[Abstract] [Full Text] -
Gilgado, F., Cano, J., Gene, J., Guarro, J.
(2005). Molecular Phylogeny of the Pseudallescheria boydii Species Complex: Proposal of Two New Species. J. Clin. Microbiol.
43: 4930-4942
[Abstract] [Full Text] -
Pitisuttithum, P., Negroni, R., Graybill, J. R., Bustamante, B., Pappas, P., Chapman, S., Hare, R. S., Hardalo, C. J.
(2005). Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother
56: 745-755
[Abstract] [Full Text] -
Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P.
(2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother
55: 317-319
[Abstract] [Full Text] -
Capilla, J., Mayayo, E., Serena, C., Pastor, F. J., Guarro, J.
(2004). A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother
54: 1092-1095
[Abstract] [Full Text] -
Simitsopoulou, M., Gil-Lamaignere, C., Avramidis, N., Maloukou, A., Lekkas, S., Havlova, E., Kourounaki, L., Loebenberg, D., Roilides, E.
(2004). Antifungal Activities of Posaconazole and Granulocyte-Macrophage Colony-Stimulating Factor Ex Vivo and in Mice with Disseminated Infection Due to Scedosporium prolificans. Antimicrob. Agents Chemother.
48: 3801-3805
[Abstract] [Full Text] -
Capilla, J., Guarro, J.
(2004). Correlation between In Vitro Susceptibility of Scedosporium apiospermum to Voriconazole and In Vivo Outcome of Scedosporiosis in Guinea Pigs. Antimicrob. Agents Chemother.
48: 4009-4011
[Abstract] [Full Text] -
Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., Courtney, R.
(2004). Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects. Antimicrob. Agents Chemother.
48: 3543-3551
[Abstract] [Full Text] -
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J. L.
(2004). In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrob. Agents Chemother.
48: 3107-3111
[Abstract] [Full Text] -
Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J.
(2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother.
48: 1188-1196
[Abstract] [Full Text] -
Courtney, R., Radwanski, E., Lim, J., Laughlin, M.
(2004). Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men. Antimicrob. Agents Chemother.
48: 804-808
[Abstract] [Full Text] -
Capilla, J., Serena, C., Pastor, F. J., Ortoneda, M., Guarro, J.
(2003). Efficacy of Voriconazole in Treatment of Systemic Scedosporiosis in Neutropenic Mice. Antimicrob. Agents Chemother.
47: 3976-3978
[Abstract] [Full Text] -
Gil-Lamaignere, C., Roilides, E., Lyman, C. A., Simitsopoulou, M., Stergiopoulou, T., Maloukou, A., Walsh, T. J.
(2003). Human Phagocytic Cell Responses to Scedosporium apiospermum (Pseudallescheria boydii): Variable Susceptibility to Oxidative Injury. Infect. Immun.
71: 6472-6478
[Abstract] [Full Text] -
Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V.
(2003). Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults. Antimicrob. Agents Chemother.
47: 2788-2795
[Abstract] [Full Text] -
Steinbach, W. J., Schell, W. A., Miller, J. L., Perfect, J. R.
(2003). Scedosporium prolificans Osteomyelitis in an Immunocompetent Child Treated with Voriconazole and Caspofungin, as Well as Locally Applied Polyhexamethylene Biguanide. J. Clin. Microbiol.
41: 3981-3985
[Abstract] [Full Text] -
Garau, M., Pereiro, M. Jr., del Palacio, A.
(2003). In Vitro Susceptibilities of Malassezia Species to a New Triazole, Albaconazole (UR-9825), and Other Antifungal Compounds. Antimicrob. Agents Chemother.
47: 2342-2344
[Abstract] [Full Text] -
Meletiadis, J., Mouton, J. W., Meis, J. F. G. M., Verweij, P. E.
(2003). In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates. Antimicrob. Agents Chemother.
47: 106-117
[Abstract] [Full Text] -
ORTONEDA, M., PASTOR, F.J., MAYAYO, E., GUARRO, J.
(2002). Comparison of the virulence of Scedosporium prolificans strains from different origins in a murine model. J Med Microbiol
51: 924-928
[Abstract] [Full Text] -
Afeltra, J., Dannaoui, E., Meis, J. F. G. M., Rodriguez-Tudela, J. L., Verweij, P. E.
(2002). In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans. Antimicrob. Agents Chemother.
46: 3323-3326
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»